Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Dodávka jídla pro léčbu diabetu u pacientů na venkovských klinikách

21. srpna 2026 aktualizováno: University of Arkansas

Naším dlouhodobým cílem je transformovat vedení venkovských obyvatel T2DM. Cílem této studie je určit účinnost intervence, která je škálovatelná a udržitelná a podporuje adherenci pacientů tím, že zmírňuje potíže účastníků s nedostatkem potravin na venkově spojené s dokončením stávajících intervencí. Naše konkrétní cíle jsou:

  1. Porovnejte účinnost intervence zdravého zásobování potravinami (HFDI) plus standardní péči a standardní péči samotnou, abyste zlepšili výsledky související s diabetem u pacientů s DM2 na venkově s nejistotou ohledně potravin. Hypotéza: Ve srovnání se samotnou standardní péčí budou pacienti dostávající HFDI plus standardní péči vykazovat zlepšené: kontrola glykémie H1 měřená pomocí HbA1c; H2 kardiometabolické rizikové faktory: krevní tlak, glukóza nalačno, lipidy nalačno a BMI; H3 self-management: sebeúčinnost, dodržování self-managementu chování a dodržování léků; Výsledky zaměřené na pacienta H4: úzkost související s diabetem, kvalita života související s diabetem a komplikace související s diabetem.
  2. Porovnejte účinnost HFDI plus standardní péče a standardní péče samotné, abyste zlepšili kvalitu stravy u venkovských pacientů s potravinovou nejistotou s T2DM. Hypotéza: Ve srovnání se samotnou standardní péčí budou pacienti dostávající HFDI plus standardní péči vykazovat zlepšení: skóre H1 Indexu zdravého stravování 2015 (HEI-2015); H2 spotřeba ovoce a zeleniny.
  3. Porovnejte nákladovou efektivitu, abyste pochopili HFDI plus náklady na standardní péči ve vztahu k výsledkům ve vztahu k samotné standardní péči. Hypotéza: HFDI bude nákladově efektivní na základě tradičních nákladů na další získaný rok života s upravenou kvalitou.

Přehled studie

Detailní popis

Type 2 diabetes mellitus (T2DM) is a growing public health concern affecting 37.3 million people (11.3%) in the United States (US). At the same time, 13.5 million (10.2%) US households experience food insecurity. People living in rural areas are particularly challenged by the intersection of food insecurity and T2DM - both food insecurity and T2DM prevalence in rural areas are higher than metropolitan areas. Arkansas has the sixth highest proportion of rural population (44.5%) of all US states, with rates of food insecurity and T2DM of 14.7% and 12.5%, respectively. Rurality and food insecurity are associated with social determinants of health that impede diabetes management (e.g., limited transportation, longer distance to healthcare clinics, lack of access to healthy food options). People experiencing food insecurity have poor diet quality (e.g., high intake of sugar-sweetened beverages and red/processed meat, low intake of fruits and vegetables), which is a key risk factor for unmanaged T2DM. Unmanaged T2DM can lead to increased risk of serious complications. Improved diet quality is a crucial factor to enhance T2DM management. Millions of people with T2DM experiencing food insecurity turn to food pantries for food; however, food pantries are not a long-term solution to improve health for rural people with T2DM experiencing food insecurity. Certified Diabetes Care and Education Specialists (CDCES; i.e., diabetes educators) have expertise in working with patients to instill knowledge and skills necessary to live an active and healthy lifestyle with T2DM.

This study used a two-arm randomized controlled comparative effectiveness design to compare the effectiveness of a Healthy Food Delivery Intervention (HFDI) plus a consultation with a CDCES Consultation Only in improving diabetes-related outcomes among rural people with T2DM experiencing food insecurity. We hypothesized HFDI to be comparatively more effective in improving HbA1c and other outcomes for rural people with T2DM experiencing food insecurity.

The primary outcome was change in hemoglobin A1c (HbA1c) between baseline and post-intervention. Secondary outcomes included diet quality (Healthy Eating Index-2015 and Veggie meter scores), body mass index, blood pressure, lipids, glucose, diabetes management self-efficacy and diabetes-related distress. We also examined the duration of treatment effects by comparing outcomes at 6 months post-intervention and 12 months post-intervention.

Participants were randomly assigned to either the HFDI arm or the CDCES Consultation Only arm. Participants randomized to the CDCES Consultation Only study arm received the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a CDCES and a food pantry resource guide specific to their community. In addition to standard of care and the CDCES consultation, participants randomized to the HFDI arm received weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total). Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.

Participants were initially recruited only from family medicine clinics within the University of Arkansas for Medical Sciences (UAMS) network that serve the highest percentage of rural patients with T2DM. Additional clinics and Federally Qualified Health Centers were added as recruitment sites in order to meet study recruitment goals.

Inclusion criteria included: 1) 18 years of age or older; 2) food insecure (Hunger Vital Sign™ 2-item screener); 3) HbA1c ≥ 6.5%; 4) speak English or Spanish; and 5) live at a rural address. Note: the food insecurity and rural residence criteria were removed during the course of the study in order to meet study recruitment goals.

Exclusion criteria included: 1) having conditions making it unlikely the participant will be able to follow the protocol, such as terminal illness, severe mental illness, severely impaired vision or hearing, eating disorder, or plans to move out of the geographic region; 2) pregnant; 3) only one adult with T2DM per household was allowed to enroll.

Investigators worked with clinical stakeholders at each clinic site to ensure the study was integrated into existing workflows. Study flyers were placed throughout the clinics, in the exam rooms, and in the clinic waiting areas. All clinics had electronic health record systems that were queried monthly for recruitment. Research coordinators at each clinic site identified potential participants by reviewing monthly patient queries and daily clinic schedules. The research coordinators provided study information to potential participants in a pre-visit call or during the clinical visit. If the patient was interested, the research coordinator scheduled a 30-minute meeting to discuss the study and conduct eligibility screening in a private room in the clinic. Research staff were trained to flag potential participants that may not meet eligibility, which were then sent to the study physician for medical determination. Those deemed eligible to participate reviewed study information with the research coordinator, were given the chance to ask questions, and signed an informed consent. All recruitment and consent information was available in English and Spanish.

Randomization was conducted by the study biostatistician, who had no interactions with potential participants and no supervisory role with study staff responsible for recruiting, consent, and intervention processes. Stratified random assignment using permuted blocks of size 2, 4, and 6 was used to randomize participants 1:1 to the treatment arms using lists created with the blockrand R package. Strata of participant sex, level of T2DM control (6.5-9.0%; >9.0%), and age group (18-64; 65+ years) were used to ensure that similar numbers within each characteristic are assigned 1:1 to the treatment arms.

Data collection occurred in-person at the clinic from which participants were recruited, co-occurring with participants' primary care provider visits when possible. Biometric and survey measure outcomes were collected at baseline (pre-intervention), immediate post-intervention (approximately 12 weeks after baseline), 6 months post-intervention, and 12 months post-intervention.

Typ studie

Intervenční

Zápis (Aktuální)

416

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Arkansas
      • Batesville, Arkansas, Spojené státy, 72501
        • UAMS - North Central
      • Corning, Arkansas, Spojené státy, 72422
        • Pocahontas Medical Center
      • Eureka Springs, Arkansas, Spojené státy, 72632
        • Washington Regional Medical Center
      • Fayetteville, Arkansas, Spojené státy, 72703
        • Washington Regional Medical Center
      • Fayetteville, Arkansas, Spojené státy, 72703
        • UAMS - Northwest
      • Fort Smith, Arkansas, Spojené státy, 72901
        • UAMS - West
      • Harrison, Arkansas, Spojené státy, 72601
        • Washington Regional Medical Center
      • Helena, Arkansas, Spojené státy, 72390
        • UAMS - East
      • Jonesboro, Arkansas, Spojené státy, 72401
        • UAMS - Northeast
      • Magnolia, Arkansas, Spojené státy, 71753
        • UAMS - South
      • Marianna, Arkansas, Spojené státy, 72360
        • Lee County Cooperative Clinic
      • Marshall, Arkansas, Spojené státy, 72650
        • Boston Mountain Rural Health Center
      • Pocahontas, Arkansas, Spojené státy, 72455
        • Pocahontas Medical Clinic

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Popis

Kritéria pro zařazení:

  • 18 let nebo starší
  • hlásit nedostatek potravin
  • report T2D (potvrzeno tím, že HbA1c je rovný nebo vyšší než 6,5 při počátečním sběru dat bezprostředně po udělení souhlasu)
  • Mluvte anglicky nebo španělsky
  • V současné době bydlí na venkovské adrese

Kritéria vyloučení:

  • podmínky, kvůli nimž je nepravděpodobné, že účastník bude schopen dodržet protokol, jako je smrtelná nemoc, těžká duševní choroba, vážně zhoršený zrak nebo sluch, porucha příjmu potravy nebo plány na přestěhování z geografické oblasti
  • Těhotná

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Podpůrná péče
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: CDCES Consultation Only
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
Participants randomized to this study arm receive the standard of care at the clinic from which they were recruited, plus a 60 minute healthy eating consultation with a Certified Diabetes Care and Education Specialist and a food pantry resource guide specific to their community.
Experimentální: Healthy Food Delivery Intervention
In addition to standard of care and the CDCES consultation, participants randomized to the Healthy Food Delivery arm receive weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).
Participants randomized to the Healthy Food Delivery Intervention receive standard of care, a CDCES Consultation, food pantry resource guide, and weekly home delivery of type 2 diabetes-appropriate food boxes over 3 months (12 food boxes in total).Each food box included approximately 9000 calories of food. Food boxes were designed by a Registered Dietician. Food boxes also included recipes and cooking tips specific to foods included in that week's box.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Hemoglobin A1c (HbA1c)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Finger stick blood collection will be used to test HbA1c using a Siemens DCA Vantage analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Diet Quality: Healthy Eating Index-2015 Score
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks)
Diet quality was assessed with a 24-hour dietary recall interview using the Nutrition Data System for Research (NDSR) software. The Healthy Eating Index-2015 (HEI) was applied to the dietary recall data to measure the extent that dietary intake among participants met the Dietary Guidelines for Americans 2015-2020 recommendations. HEI-2015 consists of 13 individual components. HEI-2015 scores have a possible range of 0-100, with higher numbers indicating better diet quality.
Baseline; Immediate post-intervention (approx. 12 weeks)
Diet Quality: Veggie Meter Score
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Skin carotenoid level was measured using a Veggie Meter optical skin scanner, which uses Raman Spectroscopy. The Veggie Meter assesses frequency changes in reflected light to calculate carotenoid presence in the skin and has been validated as a non-self-report, non-invasive measure associated with serum carotenoid levels and self-report measures of fruit and vegetable consumption. Each participant's index finger was scanned three times and the mean of the three measures was recorded for use in data analysis. Veggie Meter scores have a possible range of 0-800, with higher scores indicating better diet quality.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Body Mass Index (BMI)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Participant height (without shoes) was collected using a stadiometer and participant weight (without shoes) was collected using a calibrated digital scale. Height and weight were used to compute a continuous measure of BMI (kilograms per square meter).
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Systolic Blood Pressure (SBP)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height. Two blood pressure measurements were taken, waiting at least one minute between readings. If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken. The mean of the two (or four) measurements was recorded and used in analysis.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diastolic Blood Pressure (DBP)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Blood pressure was measured with a digital blood pressure device with the participant seated and arm elevated to place the cuff approximately at heart height. Two blood pressure measurements were taken, waiting at least one minute between readings. If there was a >5mmHg difference between the first and second reading, an additional two measurements were taken. The mean of the two (or four) measurements was recorded and used in analysis.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Total Cholesterol
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
High-Density Lipoproteins (HDL)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Low-Density Lipoproteins (LDL)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect LDL using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Triglycerides
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Glucose
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Through finger prick blood collection, point of care tests were used to collect random (non-fasting) blood glucose.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diabetes Self-Efficacy (DMSES)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
The Diabetes Management Self-Efficacy Scale (DMSES) was used to measure patient's confidence in managing their diabetes. The DMSES assesses self-reported confidence in managing multiple aspects of their diabetes. The item reponses range from 1 (not at all confident) to 10 (totally confident) and are averaged to generate composite scores, with higher scores indicating higher levels of self-efficacy.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Diabetes-Related Distress (PAID-5)
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
The Problem Areas in Diabetes scale (PAID-5) was used to measure diabetes-related distress. The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed. Item responses range from 0 (not a problem) to 4 (serious problem) and are summed to produce an overall composite score, with a total score of 8 or higher indicating possible diabetes-related emotional distress.
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Food Insecurity
Časové okno: Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention
Food insecurity was assessed using the 2-item Hunger Vital Sign. Affirmative answers ("Often True" or "Sometimes True") to either of the 2 screener items indicates food insecurity. Food insecurity was treated as a binary outcome (0=food secure, 1=food insecure).
Baseline; Immediate post-intervention (approx. 12 weeks); 6 months post-intervention; 12 months post-intervention

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Pearl A McElfish, PhD, University of Arkansas

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

22. října 2021

Primární dokončení (Aktuální)

6. února 2025

Dokončení studie (Aktuální)

18. prosince 2025

Termíny zápisu do studia

První předloženo

30. dubna 2021

První předloženo, které splnilo kritéria kontroly kvality

5. května 2021

První zveřejněno (Aktuální)

6. května 2021

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

21. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • 261074
  • 5R01NR019487 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit